NASDAQ:CLBS - Caladrius Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.98 +0.03 (+0.61 %)
(As of 01/15/2019 04:00 PM ET)
Previous Close$4.95
Today's Range$4.82 - $5.09
52-Week Range$3.05 - $11.65
Volume22,200 shs
Average Volume18,560 shs
Market Capitalization$47.63 million
P/E Ratio-2.80
Dividend YieldN/A
Beta1.44
Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLBS
CUSIPN/A
Phone(908) 842-0100

Debt

Current Ratio9.66
Quick Ratio9.66

Price-To-Earnings

Sales & Book Value

Annual Sales$35.28 million
Price / Sales1.39
Price / Cash FlowN/A
Book Value$5.30 per share
Price / Book0.94

Profitability

Net Income$22.97 million
Net MarginsN/A
Return on Assets-29.87%

Miscellaneous

Employees22
Market Cap$47.63 million
OptionableOptionable

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.20. View Caladrius Biosciences' Earnings History.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for Caladrius Biosciences.

What price target have analysts set for CLBS?

2 equities research analysts have issued twelve-month target prices for Caladrius Biosciences' stock. Their predictions range from $7.00 to $18.50. On average, they anticipate Caladrius Biosciences' stock price to reach $12.75 in the next year. This suggests a possible upside of 156.0% from the stock's current price. View Analyst Price Targets for Caladrius Biosciences.

What is the consensus analysts' recommendation for Caladrius Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Caladrius Biosciences.

Has Caladrius Biosciences been receiving favorable news coverage?

News headlines about CLBS stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Caladrius Biosciences earned a news sentiment score of 1.9 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Caladrius Biosciences' key competitors?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:
  • David J. Mazzo, President, Chief Executive Officer & Director
  • Joseph Talamo, Chief Financial Officer & Senior Vice President
  • Douglas W. Losordo, Chief Medical Officer & SVP-Regulatory Affairs
  • Greg Berkin, Vice President-Information Technology
  • John D. Menditto, Executive Director-Investor Relations

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $4.98.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $47.63 million and generates $35.28 million in revenue each year. The biotechnology company earns $22.97 million in net income (profit) each year or ($1.78) on an earnings per share basis. Caladrius Biosciences employs 22 workers across the globe.

What is Caladrius Biosciences' official website?

The official website for Caladrius Biosciences is http://www.caladrius.com.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at (908) 842-0100 or via email at [email protected]


MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  455
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/15/2019 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel